First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 18(11): 1483-1492, 2017 11.
Article
de En
| MEDLINE
| ID: mdl-28967485
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Carcinome transitionnel
/
Tumeurs urologiques
/
Anticorps monoclonaux humanisés
Type d'étude:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limites:
Aged
/
Aged80
/
Humans
/
Middle aged
Langue:
En
Journal:
Lancet Oncol
Sujet du journal:
NEOPLASIAS
Année:
2017
Type de document:
Article